Keywords: japan, mhw, mandates, panaldin, label, change, patients
Japan MHW mandates Panaldin label change
Article | 06 July 1999
Patients in Japan who are newly-prescribed Daiichi's antithrombotic drugPanaldin (ticlopidine) are now required to take a blood test every two ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
